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Single-minded 1 (SIM1) is a basic helix-loop-helix transcription factor involved in the development and func-
tion of the paraventricular nucleus of the hypothalamus. Obesity has been reported in Sim1 haploinsufficient 
mice and in a patient with a balanced translocation disrupting SIM1. We sequenced the coding region of SIM1 
in 2,100 patients with severe, early onset obesity and in 1,680 controls. Thirteen different heterozygous variants 
in SIM1 were identified in 28 unrelated severely obese patients. Nine of the 13 variants significantly reduced 
the ability of SIM1 to activate a SIM1-responsive reporter gene when studied in stably transfected cells coex-
pressing the heterodimeric partners of SIM1 (ARNT or ARNT2). SIM1 variants with reduced activity cosegre-
gated with obesity in extended family studies with variable penetrance. We studied the phenotype of patients 
carrying variants that exhibited reduced activity in vitro. Variant carriers exhibited increased ad libitum food 
intake at a test meal, normal basal metabolic rate, and evidence of autonomic dysfunction. Eleven of the 13 
probands had evidence of a neurobehavioral phenotype. The phenotypic similarities between patients with 
SIM1 deficiency and melanocortin 4 receptor (MC4R) deficiency suggest that some of the effects of SIM1 defi-
ciency on energy homeostasis are mediated by altered melanocortin signaling.
Introduction
Genetic disruption of several molecules involved in the hypotha-
lamic leptin/melanocortin pathway can cause obesity in rodents 
and humans (1). Single-minded 1 (SIM1) is a basic helix-loop-helix 
transcription factor involved in the development and function of 
the paraventricular nucleus (PVN) of the hypothalamus, a region 
that plays a critical role in energy homeostasis (2). Sim1 homozy-
gous null mice (Sim1–/–) die in the perinatal period and have abnor-
mal hypothalamic architecture, lacking paraventricular, anterior 
periventricular, and supraoptic nuclei because of failure of ter-
minal migration and differentiation of Sim1-expressing neurons 
(3). Sim1 heterozygous mice (Sim1+/–) survive and develop severe 
obesity associated with increased food intake without any measur-
able deficit in energy expenditure, establishing a role for Sim1 in 
energy homeostasis (3–5). Conditional postnatal deletion of Sim1 
in postmitotic neurons recapitulates the obesity phenotype seen 
in germline depletion of Sim1 in mice, indicating that Sim1 has a 
physiological role in energy homeostasis that is distinct from its 
role in hypothalamic development (6).
Several lines of evidence suggest that SIM1 may influence ener-
gy homeostasis by interacting with pathways involved in central 
melanocortin signaling. The obesity phenotype of Sim1+/– mice 
closely resembles that of mice lacking the melanocortin 4 receptor 
(Mc4r) with increased linear growth and increased feeding effi-
ciency in addition to an increase in food intake (3, 4, 6). However, 
in contrast to Mc4r-null mice, energy expenditure is not reduced 
in Sim1+/– mice, suggesting that the relationship between Sim1 
and Mc4r is not a simple linear one (4, 6). Sim1 is expressed in 
the PVN, basomedial amygdala, anterior hypothalamus, and lat-
eral hypothalamic area (5), regions that also have high concentra-
tions of Mc4r-expressing neurons, and Mc4r mRNA levels in the 
PVN are significantly reduced in Sim1+/– mice (6). Administration 
of melanotan II, a potent melanocortin receptor agonist, results 
in a reduction in food intake in WT mice, whereas this response 
is blunted in Sim1+/– mice, suggesting that Sim1 lies downstream 
of Mc4r (4). Transgenic overexpression of human SIM1 via a BAC 
transgene in Agouti mice (which ectopically overexpress the mela-
nocortin receptor antagonist Agouti and share many of the fea-
tures of Mc4r-null mice) ameliorates their phenotype by normal-
izing their food intake, suggesting that increased SIM1 expression 
is able to compensate for impaired Mc4r signaling (7).
There is some evidence that common variants at the SIM1 locus 
are associated with BMI (8, 9). Also, patients with chromosomal 
deletions involving 6q14–q21, a region that encompasses several 
genes including SIM1, have been reported to develop early onset 
obesity and developmental delay, with some reports suggesting 
that there is a degree of phenotypic overlap with the Prader-Willi 
syndrome (PWS) (10). In 2000, Holder and colleagues reported a 
female patient with severe early onset obesity and a de novo bal-
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anced translocation between chromosomes 1p22.1 and 6q16.2, 
which disrupted 1 allele of SIM1 (11). We previously studied 277 
patients with severe early onset obesity and identified a patient 
with a missense variant in SIM1 (I128T); however, in the absence 
of cosegregation in the immediate family, the pathogenicity of 
this variant was unclear (12). In order to comprehensively address 
whether variants in SIM1 contribute to obesity, we have now 
sequenced the SIM1 gene in a large number of patients of mixed 
European descent with severe, early onset obesity recruited to the 
Genetics of Obesity Study (GOOS) (n = 2100) and a similar num-
ber of population-based controls from a large United Kingdom 
(UK) population-based study, the Ely study (n = 1680).
SIM1 belongs to the bHLH/PAS (basic helix-loop-helix/Per-
Arnt-Sim) family of transcription factors, which are characterized 
by an N-terminal bHLH domain required for DNA binding and 
dimerization and a PAS domain that acts as a secondary dimer-
ization interface (13, 14). Transcriptional control of target genes 
requires heterodimerization with another transcription factor, 
aryl-hydrocarbon receptor nuclear translocator (ARNT), or a 
homolog prevalent in the CNS, ARNT2 (15, 16). We went on to 
characterize the functional consequences of SIM1 variants found 
in patients using a luciferase reporter gene assay. Furthermore, 
we report the clinical phenotype of individuals carrying SIM1 
variants with reduced activity and find several parallels with the 
phenotype of MC4R deficiency.
Results
Identification of SIM1 variants. The coding region of SIM1 was 
sequenced in 2,100 unrelated patients with severe, early onset obe-
sity recruited as part of GOOS and 1,680 unrelated population-
based controls; both groups were of mixed European descent. 
No nonsense or frameshift variants were found in either group. 
Multiple nonsynonymous missense variants were found in obese 
individuals (28/2100) and in controls (14/1680) (Figure 1 and 
Supplemental Table 1; supplemental material available online 
with this article; doi:10.1172/JCI68016DS1). Several of the SIM1 
variants found only in severely obese patients were predicted to be 
functionally deleterious based on SIFT (Sorting Intolerant From 
Tolerant) analysis and altered residues that were highly conserved 
across species (Supplemental Table 1), suggesting they may have 
functional consequences. Where possible, we sequenced the SIM1 
gene in available family members of severely obese probands. The 
majority of SIM1 variants found exclusively in patients cosegre-
gated with obesity in affected families with variable penetrance 
across and within families (Figure 2).
Three nonsynonymous variants were found in multiple obese 
cases, but also in controls in this study and in publicly available 
exome data: I128T (rs138546433), Q152E (rs140908824), and 
D707H (rs74726213) (Figure 1 and Supplemental Table 1). Nota-
bly, I128T has been reported at the same frequency in normal 
weight and obese populations in previous studies (9). The mean 
BMI of controls carrying these 3 variants was 27.8 ± 2.1 kg/m2; 
however, family members of controls were not available for geno-
typing, so the contribution of these variants to final body weight 
remains to be tested. Four variants were found only in controls; as 3 
of these variants were predicted to be tolerated by SIFT analysis, 
these variants were not studied further (Supplemental Table 1).
Functional properties of mutant SIM1 proteins. In order to study 
the functional properties of the mutant SIM1 proteins found in 
patients, cDNAs expressing either WT or mutant myc-epitope–
tagged SIM1 were incorporated into a single defined genetic locus 
of HEK293 Flp-In T-Rex cells, in which the expression of SIM1 
was constitutively repressed by an upstream tetracycline repressor 
element. The addition of doxycycline induced expression of SIM1 
protein of the expected approximately 85 kDa. Consistent levels 
of induction were seen with different clonal cell lines expressing 
the same protein (e.g., WT SIM1) and similar levels of expression 
were observed across the set of SIM1 mutant proteins (Figure 3A).
The bona fide DNA recognition sequence of SIM1 is unknown; 
however, it has been observed to bind the CNS midline enhancer 
element (CME) TACGTG, which is the target sequence of the dro-
sophila homolog of SIM1(17). Multimerized CME has previously 
been shown to mediate SIM1-dependent transcriptional activa-
tion of an adenovirus major late promoter–driven firefly lucifer-
ase reporter gene (pML/6C-WT) in mammalian cells (15, 18). This 
reporter plasmid and expression vectors for either ARNT or ARNT2 
were introduced into WT SIM1 inducible cells and luciferase activ-
ity measured after 16 hours treatment with doxycycline. Similar 
activity was observed with 2 independently derived WT SIM1 stable 
cell lines (data not shown), with coexpression with ARNT giving 
higher activity than coexpression of ARNT2 (data not shown).
To examine the functional consequences of the variants on 
the transcriptional activity of SIM1, we compared the ability of 
mutant SIM1 proteins to activate the pML/6C-WT reporter with 
WT SIM1 upon coexpression of either ARNT or ARNT2. While 
ARNT2 is the proposed in vivo partner of SIM1 (15), experiments 
Figure 1
Identification of SIM1 variants in this study. Sche-
matic of the domain structure of the human SIM1 
protein. SIM1 variants identified in GOOS patients 
only (black), controls only (gray), and in both 
patients and controls (underlined) are shown.
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with ARNT were also performed to independently verify the trend 
of changing activities across the set of SIM1 mutants. Nine of the 
variants showed significant reduction of transcriptional activity 
in this assay when partnered with ARNT2, with R171H resulting 
in a profound reduction of activity with both partner proteins 
(P < 0.001) (Figure 3). Activities of 3 mutant proteins, R383G, 
S541L, and R703Q, were indistinguishable from WT in these 
assays. Transcriptional activity in complex with ARNT2 was more 
severely affected than that with ARNT, although the general trend 
of comparative activities was very similar.
Interestingly, R383 forms part of a novel nuclear localization 
signal (NLS) elucidated in SIM1 and its paralog, SIM2 (19). We 
tested to determine whether loss of arginine at this position 
might disrupt nuclear translocation by 
performing immunocytochemistry on cell 
lines expressing WT SIM1-myc and R383G 
SIM1-myc (Supplemental Figure 1). While 
both WT and mutant forms of SIM1 were 
predominantly nuclear, the R383G mutant 
had increased cytoplasmic staining com-
pared with WT, suggesting less efficient 
nuclear uptake of this variant. However, 
this altered efficiency did not result in a 
decrease of activity in our reporter gene 
assays, suggesting the synthetic reporter 
system may underestimate the functional 
consequences of some variants.
Using the crystal structure for the 
N-terminal half of the CLOCK/BMAL 
heterodimer, we constructed a homology 
model to predict the likely structural fea-
tures of the SIM1/ARNT2 bHLH/PAS-A 
heterodimer. This revealed the N-terminal 
amino acids that harbor variants, S71, 
I128, Q152, and R171, are likely to lie on 
the surface of the protein (Figure 3D). It is 
therefore possible that these amino acids 
contact accessory proteins important for 
SIM1 function. S71, I128, and Q152 are 
all situated in unstructured loops (Figure 
3, E and F), making it difficult to predict 
how these variants might influence SIM1 
structure. In contrast, R171 is situated in 
a helix that is in close proximity to other 
helices that make up PAS-A of SIM1 and is 
within range for intramolecular hydrogen 
bonding with both the peptide backbone 
and other residues (Figure 3E). Thus, the 
least active variant in the reporter assay, 
R171H, may contain a destabilized PAS A 
helix, which could weaken dimerization and/or decrease overall 
protein stability. As crystal structures show very different PAS B 
interactions for each of HIF/Arnt PAS B (20), CLOCK/BMAL 
PAS B (21), and the Per PAS A.PAS B homodimer (22), we have 
not attempted modeling beyond PAS-A. Modeling was not pos-
sible for the C terminus, as there are no structures of this region 
for any member of the protein family.
Phenotype of SIM1 variant carriers. Patients harboring variants with 
reduced activity in SIM1 and their relatives were invited for clini-
cal studies including measurement of body composition, energy 
intake, energy expenditure, and endocrine function (Supplemen-
tal Table 1). Given the evidence suggesting that Sim1 is involved 
in melanocortin signaling in rodents, we compared the data from 
Figure 2
Pedigrees of families of SIM1 variant carriers. 
Squares and circles represent male and female 
family members, respectively. Black symbols 
denote family members with obesity, arrows indi-
cate probands. Below each individual, the age 
and BMI (SD score for children) is given along 
with genotype, where N represents a normal 
SIM1 allele and M represents a mutant allele.
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patients carrying SIM1 variants that exhibited reduced activity in 
vitro to that obtained from patients with MC4R deficiency as well 
as comparably obese subjects with WT MC4R and SIM1 sequences, 
studied using the same methods.
Anthropometry and body composition. All SIM1 probands had 
increased body weight, deviating from predicted percentiles 
within the first 2 years of life. The mean BMI SD score of SIM1 
variant carriers was 4.4 ± 0.4. In childhood, linear growth was nor-
mal; mean height SD scores for prepubertal children with SIM1 
variants (0.96 ± 0.35) were comparable to those of equally obese 
children without SIM1 variants (Figure 4). Final height in SIM1-
deficient adults was not increased (Figure 4). The lack of acceler-
ated linear growth in patients with SIM1 mutations contrasts with 
the phenotype of the patient reported by Holder et al. (11) and 
the phenotype of Sim1 heterozygous mice. This difference may be 
explained by partial versus complete loss of SIM1 activity.
Figure 3
Variants in SIM1 significantly reduce transcriptional activation. (A) Western blot analysis of Myc-tagged SIM1 expression in whole-cell extracts 
from doxycycline-induced 293 Flp-In T-Rex cells. (B and C) Two independently derived WT SIM1 293 Flp-In T-Rex stable cell lines, 13 different 
SIM1 mutant 293 Flp-In T-Rex stable cell lines, and 1 empty vector cell line were transiently transfected with SIM1 luciferase reporter plasmid, 
Renilla control plasmid, and either ARNT (B) or ARNT2 (C) expression plasmid. Cells were then stimulated with doxycycline and analyzed for 
luciferase activity. Bars represent the mean Firefly/Renilla value expressed relative to WT, which has been normalized to 100%. Results shown 
are the average of at least 3 experiments performed in triplicate + SEM, expressed relative to the 2 WT lines, which have been combined 
into a single average value and normalized to 100%. Log values generated for each mutant were compared with WT. *P < 0.05; **P < 0.01; 
***P < 0.001. (D) Homology model of the SIM1 ARNT2 PAS-A heterodimer. SIM1 is shown in yellow and ARNT2 is shown in green, with amino 
acids that contain point variants colored red. (E and F) Ribbon diagrams of the SIM1 ARNT2 PAS-A heterodimer, with amino acids that contain 
point variants depicted as sticks colored pink.
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We measured the body composition of SIM1 variant carriers by 
dual energy X-ray absorptiometry (DEXA). The mean percentage of 
body fat among SIM1 variant carriers was high at 45.8 ± 3.2 percent 
(normal range, 15 to 25 percent; P < 0.001) and comparable to that 
seen in patients with heterozygous MC4R variants (46.5 ± 2.2).
Energy intake and energy expenditure. All subjects had a history 
of increased food-seeking behavior in childhood, which contin-
ued into later life in the subset of adult subjects. The energy con-
sumed by carriers of SIM1 variants at an 18MJ ad libitum test meal 
given after an overnight fast was significantly greater than that 
of normal weight control subjects, after adjustment for lean body 
mass (Figure 5A). In this test, energy intake was comparable with 
MC4R-deficient patients. Basal metabolic rate (BMR) measured 
by indirect calorimetry was identical to that predicted based on 
the basis of age, sex, and body composition in children and adults 
(Figure 5B). The respiratory quotient (ratio of carbohydrate to 
fat oxidation) was significantly increased in SIM1 variant carri-
ers compared with obese controls, but comparable to that seen in 
MC4R-deficient patients (Figure 5C).
Metabolic and endocrine function. Most of the subjects with SIM1 
deficiency were euglycemic, although 1 adult had developed 
impaired glucose tolerance. All patients were hyperinsulinemic, 
but to a degree that was consistent with the degree of obesity (Fig-
ure 6). This contrasts with the severe disproportionate hyperin-
sulinemia we have previously reported in MC4R deficiency (23). 
Basal and thyrotrophin-releasing hormone-stimulated thyroid-
stimulating hormone (TSH) levels were within normal limits, as 
were circulating levels of free thyroxine (data not shown).
Autonomic dysfunction. We studied blood pressure after an over-
night fast in the recumbent position in SIM1 variant carriers, MC4R-
deficient patients, and obese controls (Figure 7). Mean systolic 
blood pressure was lower in SIM1 variant carriers than in obese con-
trols; diastolic blood pressure measurements were not statistically 
different from those of controls (Figure 7, A and B). These observa-
tions are consistent with our previous observations in MC4R-defi-
cient patients (24). To further examine autonomic nervous system 
function in SIM1 variant carriers, we measured heart rate variability 
at beat-to-beat resolution over 24 hours using a portable monitor. 
During sleep, there were no significant group differences in average 
heart rate, the high-frequency (HF) component of heart rate vari-
ability, and the root mean square of successive differences (RMSSD) 
between adjacent R-R intervals (predominantly measures of para-
sympathetic activation) (data not shown). On waking, the heart 
rate increased in all 3 groups, but the magnitude of the increase was 
attenuated in SIM1 variant carriers and in MC4R-deficient patients 
compared with obese controls (Figure 7C). These findings are con-
sistent with impaired sympathetic tone in these subjects.
Neurobehavioral abnormalities. Eleven of the 13 probands who 
agreed to further studies had a degree of cognitive deficit as 
reported by physicians and family members. All of these patients 
carried variants that were associated with reduced activity in vitro 
(Supplemental Table 1). A spectrum of behaviors was seen, includ-
ing impaired concentration, memory deficit, emotional lability, 
and in some cases, autistic spectrum behavior. Some of these fea-
tures overlap with those reported in PWS, but of note, none of the 
patients had a reported history of hypotonia or feeding difficulties 
in early life that are hallmarks of PWS. Further behavioral testing 
was not possible as part of this study.
Discussion
In the present study, we sequenced the coding region of the tran-
scription factor SIM1 in 2,100 patients of mixed European descent 
Figure 4
Measures of height SD scores of MC4R-deficient patients, SIM1 variant 
carriers, and obese control subjects. Values are mean ± SEM. ***P < 0.001.
Figure 5
Phenotype of SIM1 variant carriers. (A) Ad libitum energy intake at 
an 18MJ test meal. Intake is expressed as kj/kg lean mass in SIM1 
variant carriers (n = 23) as compared with leptin-deficient patients 
(n = 5), MC4R-deficient patients (n = 42), and control subjects (n = 25). 
Values are mean ± SEM. **P < 0.01. (B) Measured versus predicted 
BMR adjusted for kilograms of fat free mass in SIM1 variant carriers. 
(C) Respiratory quotient as measured by indirect calorimetry in SIM1 
variant carriers (n = 25), MC4R-deficient patients (n = 82), and obese 
control subjects (n = 25). Values are mean ± SEM. *P < 0.05.
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with severe, early onset obesity from the GOOS cohort and 1680 
patients from a UK population-based control cohort. Cosegregation 
studies in families of SIM1 variant carriers indicated a dominant 
form of inheritance with variable penetrance. Some rare variants 
found in patients were also found in controls (e.g., I128T, Q152E, 
D707H). These variants are unlikely to be sufficient to explain the 
severe obesity in patients in this study, although they may be con-
tributors to overweight/obesity in individuals with a susceptible 
genetic background. The SIM1-containing locus has not emerged 
from genome-wide association studies of BMI and 2 large studies in 
European populations have failed to find a significant association 
between common variants in SIM1 and increased BMI (25).
To explore the functional consequences of these variants, we 
generated stable cell lines expressing the mutant SIM1 proteins 
and tested their ability to activate the transcription of a SIM1-
responsive reporter gene. Of the 13 variants examined, 9 had 
significantly reduced activity in this assay when paired with the 
proposed in vivo partner, ARNT2. A tenth variant, P497R, showed 
reduced activity but reached significance at P < 0.05 only with 
ARNT. No variants were found in the bHLH domain of the pro-
tein in this study, which mediates DNA binding and dimerization 
with ARNT and ARNT2. We identified 1 missense variant, S71R, 
in the sequence between the bHLH domain and the PAS region. 
This variant has weak activity, implying that this stretch of resi-
dues has a hitherto unrecognized functional role.
Three variants (I128T, Q152E, and R171H) were identified in 
the PAS-A domain and 1 (L238R) in the PAS-B domain. The PAS 
domains form conserved 3D folds and have been shown to per-
form multiple functions in bHLH/PAS proteins, including ligand 
binding (in the aryl hydrocarbon receptor), stabilization of het-
erodimerization (in CLOCK/BMAL; ref. 21), and interaction with 
either transcription coactivators (HIF-1A/ARNT; ref. 26) or repres-
sive proteins (Cry interaction with Clock; ref. 27). All 4 PAS region 
variants decreased SIM1 function, with R171H having the most 
profound effect on transcriptional activation. These findings sug-
gest that the PAS-A and PAS-B domains in human SIM1 play a 
critical structural or functional role or roles that merit further 
investigation. Interestingly, I128T and Q152E were also found in 
controls, some, but not all, of whom were obese. The contribution 
of these variants to final body weight remains to be tested.
The remaining variants were found in the C terminus which is 
thought to be responsible for transcriptional regulation. R550H, 
D707H, and T712I were the most severely impaired, suggesting 
these are crucial residues in transcriptional regulation. As with 
other bHLH/PAS proteins (28, 29), there is evidence that the 
C terminus functions primarily as a transactivation or transrepres-
sion domain. By analogy, the closely related bHLH/PAS transcrip-
tion factor SIM2 is known to regulate transcription differentially 
in a context-dependent manner (30, 31). SIM1 has variously been 
shown to activate and repress transcription in cell-based reporter 
assays. In addition to the reporter assays shown in Figure 3B, Ema 
et al. (32) showed that Sim1 repressed the ability of a Gal4-ARNT 
fusion protein to activate a Gal4 reporter gene, while deletion of 
the C terminus of Sim1 abolished this repression. The altered 
activities of our C-terminal SIM1 variants confirm the need to 
embark on experiments aimed at discovering SIM1 interacting 
proteins and direct target genes.
The activity of 3 of the variant SIM1 proteins (R383G, S541L, 
R703Q), was indistinguishable from that of WT in assays with 
Figure 6
Fasting plasma insulin in MC4R-deficient patients, SIM1 variant carri-
ers, and obese control subjects. ***P < 0.001. Values are mean ± SEM.
Figure 7
Autonomic function in SIM1 variant carriers. Measures of systolic (A) 
and diastolic (B) blood pressure are shown for SIM1 variant carriers 
(n = 23), MC4R deficient patients (n = 42) and obese control subjects 
(n = 25). (C) Heart rate during sleep and in the awake state is shown for 
SIM1 variant carriers (n = 23), MC4R-deficient patients (n = 42), and 
obese control subjects (n = 25). Values are mean ± SEM.
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ARNT or ARNT2. It is possible that these variants are not patho-
genic — there were no family data or detailed phenotypic data avail-
able for these patients, as they did not consent to further investiga-
tion (Supplemental Table 1). Alternatively, these variants may have 
a selective effect on aspects of SIM1 function that were not evalu-
ated in our system. It is important to consider that, while this assay 
exclusively examined the transactivation properties of SIM1, the 
physiological relevance of this function remains to be established.
We have linked the development of severe early onset obesity 
with naturally occurring rare variants in SIM1 that cause reduced 
activity of this transcription factor. We report variants that reduce 
activity to varying degrees, from severely damaging variants that 
are likely to be major drivers of severe obesity (S71R, R171H, 
L238R, P497R, R550H, T712I) through moderately damaging vari-
ants that in some cases demonstrate variable penetrance (D707H) 
to variants that appear to result in a small reduction in activity 
whose precise contribution to obesity in carriers remains to be 
established (I128T, Q152E, R383G, S541L, P692L, R703Q). The 
reporter gene assay used in these studies can identify variants that 
are clearly deficient in activity, but may not be able to differentiate 
variants with mild loss of activity compared with WT SIM1. Given 
their location in the structure of SIM1, it is likely that some SIM1 
variants may reduce function of the protein through a number of 
different mechanisms not tested here, including protein turnover, 
nuclear translocation, dimerization, DNA binding and binding to 
as-yet-unknown transcription cofactors.
Cumulatively, our genetic and functional data, together with the 
findings of Bonnefond and colleagues (33), provide direct evidence 
for a role for SIM1 in the control of energy homeostasis in humans. 
SIM1 is expressed in several regions of the brain, including the PVN 
of the hypothalamus, which is involved in the regulation of food 
intake. Mouse models have shown Sim1 to play both a develop-
mental and a postnatal physiological role in this nucleus (2–4, 6, 
34), with evidence divided as to whether 1 functional copy of Sim1 
is sufficient for its developmental function (4, 35). Consistent with 
postnatal deletion of Sim1 causing hyperphagia (6), stereotaxic 
injection of an adenovirus expressing shRNA directed against Sim1 
into the PVN has shown that reduction of Sim1 expression in a sub-
set of neurons is sufficient to affect food intake (36)
Ad libitum energy intake was increased in patients with SIM1 
variants with no evidence of a defect in basal energy expenditure. 
SIM1 variant carriers had lower blood pressure measurements, 
showed an attenuated increase in heart rate on waking, and had 
increased respiratory quotients when compared with obese con-
trols. These later phenotypic characteristics were shared with 
MC4R-deficient patients and are indicative of underlying auto-
nomic dysfunction that is seen in animals and humans with 
reduced melanocortinergic tone (24). These findings are consis-
tent with a body of evidence that suggests a role for SIM1 in cen-
tral melanocortin signaling.
Our results suggest that SIM1, or an as-yet-unidentified tran-
scriptional target of SIM1, forms part of the melanocortin signal-
ing pathway. The melanocortin agonist MTII and leptin admin-
istration have been shown to increase Sim1 gene expression in 
rodents, suggesting that Sim1 is upregulated as a consequence 
of Mc4r activation(4). While the interaction between SIM1 and 
MC4R may operate at a number of levels, rescue of Mc4r expres-
sion selectively in Sim1-expressing neurons in Mc4r-knockout mice 
normalizes food intake and improves the body weight phenotype 
(37). This implies that Mc4r and Sim1 are coexpressed in a sub-
set of neurons and that Mc4r in these neurons is critical to the 
central melanocortin pathway, which influences body weight by 
modulating food intake independently of energy expenditure (37). 
However, targeted ablation of Sim1-expressing neurons with diph-
theria toxin resulted in obesity resultant from both hyperphagia 
and reduced energy expenditure, suggesting additional Sim1 inde-
pendent roles exist in at least some Sim1-expressing neurons to 
regulate energy balance (38).
SIM1 patients share many features of melanocortin-deficient 
patients, but notably do not share the accelerated linear growth 
and increased final height seen in MC4R deficiency (23). Further 
experiments are needed to elucidate the precise nature of the inter-
action between MC4R and SIM1 and the common pathways acti-
vated by MC4R and SIM1.
The transcriptional targets of SIM1 are unknown; however, the 
anorexigenic neuropeptide oxytocin is a potential candidate, as 
the hyperphagia of Sim1 haploinsufficient mice is partly amelio-
rated by the central administration of oxytocin and exacerbated by 
the administration of an oxytocin receptor antagonist (39). PVN 
oxytocin neurons are activated by the central administration of a 
selective Mc4r agonist in mice; however, it is unclear whether oxy-
tocin levels are modulated independently, or as a consequence, of 
defective melanocortin signaling. Impaired oxytocinergic signal-
ing is one mechanism implicated in the hyperphagia and obesity 
seen in PWS, a clinical syndrome caused by lack of expression of 
a cluster of maternally imprinted snoRNAs on chromosome 15, 
which are thought to be involved in alternative mRNA splicing 
(40). Patients with PWS have a distinctive appearance, with obe-
sity, short stature, small hands, and characteristic facial features. 
They have developmental delay with prominent behavioral abnor-
malities, such as obsessive compulsive–type behaviors and emo-
tional lability (40). Some of these features are reminiscent of the 
cognitive and behavioral deficits seen in SIM1 variant carriers that 
were varied in manifestation and severity and could be influenced 
by impaired oxytocinergic signaling. The neurobehavioral features 
of SIM1 variant carriers are not recognized features of MC4R 
deficiency, implying that MC4R, SIM1, and OXT are unlikely to 
interact in an exclusively linear pathway. Further characterization 
of these features will have implications for the identification of 
patients in whom variants in SIM1 should be considered and for 
genetic counseling of SIM1 variant carriers.
Our data demonstrate that rare variants in SIM1 are associated 
with severe obesity and should be considered in patients with 
hyperphagic obesity of early onset. The study of patients with 
SIM1 variants that exhibit reduced activity in vitro provides strong 
evidence that this transcription factor plays a physiological role 
in central melanocortin signaling in a specific pathway that regu-
lates food intake independently of energy expenditure, although 
the precise details of this circuitry remain to be established. Iden-
tifying the direct transcriptional targets of SIM1 will be critical to 
understanding the molecular mechanisms underlying its role in 
the regulation of food intake and body weight.
Methods
Subjects. The GOOS is a cohort of individuals with severe early onset obe-
sity. Age of obesity onset is less than 10 years. Severe obesity is defined as 
BMI (weight in kilograms divided by the square of the height in meters) SD 
score greater than 3. SD scores were calculated according to the UK refer-
ence population. 2,100 patients from the cohort of European descent were 
randomly selected for SIM1 screening. Variants in genes that are known to 
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The 2 structures were then docked to using the CLOCK-BMAL structure 
as a guide. Further regularization and model refinement was carried out to 
ensure the integrity of the dimer interface. Finally, several loops were subject 
to loop modeling to improve clashing at the dimer interface using the ICM-
Pro loop modeling utility (43). Figure 3, D–F was created using PyMOL (The 
PyMOL Molecular Graphics System, Version 1.2r3pre; Schrödinger, LLC).
Metabolic phenotyping of patients. Subjects were invited to participate in 
clinical studies at the Wellcome Trust Clinical Research Facility at Adden-
brooke’s Hospital (Cambridge, UK). Weight and height were measured 
barefoot in light clothing. DEXA (DPX software; Lunar Corp) was used to 
determine body composition. Ad libitum energy intake was assessed using 
a breakfast meal of known macronutrient content after an overnight fast 
and was expressed per kilogram of lean body mass as measured by DEXA 
to allow comparison between individuals of different body weights and 
compositions. BMR and respiratory quotient were determined by indirect 
calorimetry after an overnight fast using an open circuit, ventilated canopy 
measurement system (Europa Gas Exchange Monitor; NutrEn Technology 
Ltd.). After adjustment for body composition, BMR was compared with pre-
dicted metabolic rate based on age- and sex-specific equations. Blood pres-
sure was measured using automated brachial (DINAMAP; GE Healthcare) 
or wrist (OMRON Healthcare) monitors. Heart rate was recorded using a 
wearable sensor (Actiheart; CamNtech Ltd.) from which heart rate variabil-
ity parameters were derived from cleaned inter-beat interval time series (44).
Statistics. For reporter assays, univariate ANOVA was performed on the 
log values generated for each mutant with reference to WT using SPSS 
17.0. For clinical measurements, values were compared using the unpaired 
2-tailed Student’s t test (P < 0.05 deemed significant).
Study approval. All studies were approved by the Cambridge Regional Eth-
ics Committee and were conducted in accordance with the principles of the 
Declaration of Helsinki. Each subject, or his or her parent for those under 
16, provided written informed consent; minors provided oral consent.
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cause monogenic obesity were excluded. The Ely study is a prospective pop-
ulation-based cohort study of the etiology and pathogenesis of type 2 dia-
betes and associated conditions in UK residents of mixed European descent.
Gene screening. The coding region of the human SIM1 gene (NM 005068) 
was screened in genomic DNA isolated from whole-blood lymphocytes by 
direct nucleotide sequencing at the Wellcome Trust Sanger Institute.
Cell culture and generation of stable cell lines. Cell lines were maintained in 
DMEM (Invitrogen) supplemented with 10% FBS (Gibco; Invitrogen), 10,000 
U/ml penicillin, and 10 mg/ml streptomycin (Invitrogen). Doxycycline-induc-
ible stable cell lines were established using the human embryonic kidney 293 
Flp-In T-Rex cell system (Invitrogen) as per the manufacturer’s instructions.
Plasmid construction. Full-length hSIM1 cDNA, a gift from S.E. Antonarakis 
(Department of Genetics, University of Geneva, Geneva, Switzerland), was 
modified to encode a 2xMyc tag at the 3′ end and subcloned into pcDNA5-
FRT-TO (Invitrogen). pcDNA5-FRT-TO-hSIM1-Myc was used to generate 
stable cell lines. Point variants within the hSIM1 coding sequence were intro-
duced into pcDNA5-FRT-TO-hSIM1-Myc using overlap extension PCR. Full 
details of primer sequences used are included in Supplemental Table 2.
pEF-hARNT-IRES-neo has been previously described (20). pEF-
hARNT2-IRES-neo was constructed by amplifying full-length human 
ARNT2 from 293T cDNA using primers 5′-TAACGCGTCAAGCGGGC-
GCCTATC-3′ and 5′-CGTCTAGACTACTCAGAAAACGG-3′, digesting 
with MluI/XbaI, and ligating into similarly digested pEF-IRES-neo (Gen-
bank Y11035.1). pML/6C-WT was a gift from J. Pelletier (Department of 
Biochemistry, McGill University, Montreal, Canada).
Transfection and luciferase assays. Cells were transfected with 400 ng 
pML/6C-WT, 0.5 ng phRL-CMV (Promega), and either 20 ng pEF-hARNT-
IRES-neo or 50 ng pEF-hARNT2-IRES-neo using Fugene6 (Roche). Six 
hours later, cells were induced with doxycycline (Sigma-Aldrich) at 1 μg/
ml. Cells were harvested after 16 hours doxycycline treatment and assayed 
for luciferase activity using the Dual Luciferase Assay System (Promega). 
Cell lines were assayed in triplicate in at least 3 independent experiments. 
Firefly luciferase activity was normalized to Renilla luciferase activity for 
each well (relative luciferase units), and the 3 values were averaged. In the 
case of the 2 WT lines, values for all 6 wells were averaged. These data were 
converted to log values for the purposes of statistical analysis.
Immunoblotting. Following 16-hour doxycycline treatment (1 μg/ml), 
whole-cell extracts were prepared as previously described (41). Samples were 
subjected to SDS-PAGE, transferred to nitrocellulose, and immunoblotted 
using anti-Myc 4A6 antibody (Millipore) and anti-ARNT2 M-165 l anti-
body (Santa Cruz Biotechnology Inc.). Anti–α-tubulin antibody MCA78G 
(AbD Serotec) was used to detect tubulin as a loading control.
Immunocytochemistry. Cells were grown on glass coverslips coated with 
gelatin and treated with 1 μg/ml doxycycline for 16 hours prior to fixing 
with 4% PFA. Fixed cells were stained with α-Myc-tag primary antibody (4A6, 
1:500; Millipore) and Alexa Fluor 594 α-mouse secondary antibody (1:1000). 
Coverslips were mounted with ProLong Gold antifade reagent with DAPI 
(Invitrogen), and images were taken with a Zeiss Axioplan2 microscope.
Homology modeling. Homology modeling was carried out in the ICM-
Pro program suite using the homology add-on (42). Each model of the 
heterodimer was first created individually using the sequence for human 
SIM1 residues 1–225 (Uniprot number P81133) and for human ARNT2 
residues 1–330 (Uniprot number Q9HBZ2) to include the bHLH and PASA 
domains of each protein. Homologous structures were searched for in the 
pdb, and the CLOCK-BMAL structure was the closest homologous structure 
(PDB:4F3L) (21). A homology model of SIM1 was created using the CLOCK 
protein as a 3D template, and the ARNT2 model was created using BMAL 
as a 3D model. After creation of the individual models, they were subject to 
regularization and model refinement within ICM-Pro (to optimize model 
geometry, carry out energy minimization, and alleviate clashing side-chains). 
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